- Company
- Korean pharma industry expands R&D investments
- by Chon, Seung-Hyun May 19, 2023 05:47am
- Pharmaceutical companies have vigorously engaged in research and development (R&D) activities to discover future foods. 7 out of 10 major traditional pharmaceutical companies increased their R&D investment compared to last year. R&D expenditures have increased significantly due to the development of new drugs and the introduction of new R&D pipe
- Company
- 90% of pricing managers unsatisfied with new drug price
- by Eo, Yun-Ho May 19, 2023 05:46am
- Study results showed that about 90% of the drug pricing managers in Korea are not satisfied with the value recognized for new drugs. Recently, a study on ‘'An Industry Survey on Unmet Needs in South Korea’s New Drug Listing System' was published on the online version of the medical science journal Springer (https://link.springer.com/art
- Company
- Ibrance emerges as a new drug partner for metastatic breast
- by Jung, Sae-Im May 19, 2023 05:46am
- CDK4/6 inhibitor Ibrance is emerging as a combination partner for metastatic breast cancer drug developers based on its long-accumulated treatment experience. Even if the dose is increased, there is little concern about side effects, so it is expected that it will be used as a variety of combination drugs. Ibrance is the first CDK4/6 inhibit
- Company
- Chong Kun Dang has the domestic license for the 110 billion
- by Chon, Seung-Hyun May 18, 2023 05:44am
- Chong Kun Dang bought the domestic license for MSD’s blockbuster diabetes treatment ‘Januvia series’. It is equipped with a stable cash cow that raises more than 100 billion won a year. Chong Kun Dang signed a license agreement with MSD headquarters in Switzerland to introduce all domestic rights for three diabetes treatments, Januvia, Janume
- Company
- Benefit extended DM Drug
- by Moon, sung-ho May 17, 2023 05:38am
- Clinical sites are busy finding the optimal prescription combination while the expansion of diabetes treatment reimbursement standards for each class and the release of generics following the patent expiration of original items coincided. It is an effort to find the optimal combination for each treatment category that can be covered by health
- Company
- SK Bioscience & MSD signed a consignment production contract
- by Jung, Sae-Im May 17, 2023 05:38am
- At the contract signing ceremony held in Jongno-gu, Seoul, government officials such as Second Vice Minister of Health and Welfare Park Min-soo, MSD Vice President Sanat Chattopadhyay, Hilleman Research Center CEO Raman Rao, SK Discovery Vice Chairman Choi Chang-won, SK Bioscience President Ahn Jae-yong, Hoon Kim, CEO of Global R&BD, etc. att
- Company
- Duloxetine shows strength in ₩30B antidepressant mkt
- by Nho, Byung Chul May 17, 2023 05:38am
- Last year, top-line sales of the antidepressant duloxetine recorded KRW 17.7 billion, taking a big lead ahead of venlafaxine, which achieved KRW 12.7 billion in sales, and is solidifying its position in the relevant prescription market. According to drug distribution data, sales of duloxetine drugs grew from KRW 15.5 billion to KRW 17.7 b
- Company
- Hemophilia drug Hemlibra coverage expansion
- by Chon, Seung-Hyun May 17, 2023 05:37am
- JW Pharmaceutical has laid the foundation for developing Hemlibra, a treatment for hemophilia, into a large-scale product. With the expansion of benefits, treatment benefits are provided to more patients, and expectations for sales growth are rising due to increased prescriptions. According to the Ministry of Health and Welfare on the 16th,
- Company
- Crysvita, the first fast-track drug by Yoon gov, is expected
- by Eo, Yun-Ho May 16, 2023 09:06pm
- It is now possible to prescribe 'Crysvita', the No. 1 rapidly registered drug of the Yoon government. This drug recently passed the Drug Committee (DC) of medical institutions such as SNUH. Kyowa Kirin Korea's (XLH rickets treatment Crysvita is a pediatric treatment that has been clinically proven effective in the field of diseases for whi
- Company
- JAKi Cibinqo owns strengths in dosage adjustments
- by Jung, Sae-Im May 16, 2023 05:40am
- Pfizer's JAK inhibitor ‘Cibinqo (abrocitinib)' has embarked on a full-fledged journey to expand its prescriptions. After landing in major general hospitals at the end of last year, the drug is likely to be registered for reimbursement within the first half of this year. Cibinqo is a Janus kinase 1 (JAK1) inhibitor approved by the Ministry
